A double blind study on azathioprine efficacy in multiple sclerosis

final report

C. Milanese, L. La Mantia, A. Salmaggi, M. Eoli

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.

Original languageEnglish
Pages (from-to)295-298
Number of pages4
JournalJournal of Neurology
Volume240
Issue number5
DOIs
Publication statusPublished - May 1993

Fingerprint

Azathioprine
Double-Blind Method
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Survival Analysis
Disease Progression
Recurrence
Therapeutics

Keywords

  • Azathioprine
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

A double blind study on azathioprine efficacy in multiple sclerosis : final report. / Milanese, C.; La Mantia, L.; Salmaggi, A.; Eoli, M.

In: Journal of Neurology, Vol. 240, No. 5, 05.1993, p. 295-298.

Research output: Contribution to journalArticle

Milanese, C. ; La Mantia, L. ; Salmaggi, A. ; Eoli, M. / A double blind study on azathioprine efficacy in multiple sclerosis : final report. In: Journal of Neurology. 1993 ; Vol. 240, No. 5. pp. 295-298.
@article{172d3ba33acb4ead8f8797cee9a5a4da,
title = "A double blind study on azathioprine efficacy in multiple sclerosis: final report",
abstract = "Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.",
keywords = "Azathioprine, Multiple sclerosis",
author = "C. Milanese and {La Mantia}, L. and A. Salmaggi and M. Eoli",
year = "1993",
month = "5",
doi = "10.1007/BF00838165",
language = "English",
volume = "240",
pages = "295--298",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "5",

}

TY - JOUR

T1 - A double blind study on azathioprine efficacy in multiple sclerosis

T2 - final report

AU - Milanese, C.

AU - La Mantia, L.

AU - Salmaggi, A.

AU - Eoli, M.

PY - 1993/5

Y1 - 1993/5

N2 - Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.

AB - Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.

KW - Azathioprine

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0027180925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027180925&partnerID=8YFLogxK

U2 - 10.1007/BF00838165

DO - 10.1007/BF00838165

M3 - Article

VL - 240

SP - 295

EP - 298

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 5

ER -